EVHHIGH SIGNALFINANCIAL10-K

EVH's stockholders' equity dropped substantially from $1.0B to $415.2M, indicating a major balance sheet deterioration that warrants immediate investor attention.

The dramatic decline in stockholders' equity coupled with meaningful reductions in total assets and current liabilities suggests EVH may have undergone a significant restructuring, major writedown, or other material corporate action. The 5 million share reduction in outstanding stock (from 116.6M to 111.6M shares) indicates potential share repurchases, which could partially explain the equity decline if funded through cash or debt.

Comparing 2026-02-25 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

EVH's balance sheet shows concerning deterioration with stockholders' equity falling substantially while total debt increased by 33% to $294M. Total assets declined meaningfully to $1.9B, though the company improved its cash position to $152M. The reduction in current liabilities alongside lower receivables may reflect operational scaling or collection improvements, but the overall financial picture suggests significant balance sheet stress that requires careful monitoring.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-58.5%
$1.0B$415.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
-46.2%
$715.5M$385.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+45.7%
$104.2M$151.9M

Cash position surged 45.7% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+32.9%
$221.0M$293.7M

Debt increased 32.9% — substantial leverage increase; assess whether deployed for growth or covering losses.

Total Assets
Balance Sheet
-25.4%
$2.5B$1.9B

Total assets contracted 25.4% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
-25.3%
$414.7M$309.9M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Assets
Balance Sheet
-16.6%
$607.1M$506.4M

Current assets declined 16.6% — monitor working capital adequacy and short-term liquidity.

SG&A Expense
P&L
+15.5%
$263.1M$303.9M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-21
ADDED
As of February 16, 2026, there were 111,638,338 shares of the registrant s Class A common stock outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 42 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 108 9A.
Our acquisitions have been focused on companies with extensive experience assisting customers in managing the large and complex specialties of oncology, cardiology, radiology, musculoskeletal, physical medicine, and genetics care.
We have one operating segment and one reportable segment as our chief operating decision maker ( CODM ), who is our Chief Executive Officer, assesses the performance of our operations, develops strategy and reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources.
+7 more — sign up free →
REMOVED
As of February 14, 2025, there were 116,591,148 shares of the registrant s Class A common stock outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 47 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 115 9A.
In October 2021, we acquired Vital Decisions, a leading provider of technology-enabled advance care planning services.
In August 2022, we acquired IPG, a leader in providing surgical management solutions for musculoskeletal conditions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →